Vanda's latest study failed. But revenue grew in 2019.

Washington Business Journal

Feb 26, 2020

The D.C. biotech's phase 3 clinical trial of a drug candidate failed to reduce symptoms among adult patients with an itchy skin condition called atopic dermatitis.